

H K E C L E H K L

FOSUNPHARMA 复星医药

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(P C)

(Stock Code: 02196)

2014 FIRST QUARTERLY REPORT

1.0 (2) 1.10 G
K m I I rm
A I I rm
5 1
K).

201 rm (Gr) .
* (“Company”, b A “Group”).
b

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
C

A b.
2 r. 201

A M. C M. F ; -
M. G G , M. , M. G , M. P M. K L ;
- M. H J , D. , M. L M - A D M.
C H .

* F

1 IMPORTANT NOTICE

1.1 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1.2 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1.3 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1.4 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDINGS OF THE COMPANY

2.1 Major financial information of the Group

	As at the end of the Reporting Period	As at the end of the previous year	Change recorded at the end of the Reporting Period compared with the end of the previous year (%)
Revenue (RMB million)	10,052,255,112	2,510,011,111	1.0
Profit attributable to equity holders of the parent (RMB million)	15,211,111	15,211,111	1.0
	From the beginning of the year to the end of the Reporting Period (Jan - Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar)	Year-on-year change (%)
Profit attributable to equity holders of the parent (RMB million)	102,511	102,511	-0.1
	From the beginning of the year to the end of the Reporting Period (Jan - Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar)	Year-on-year change (%)
Profit attributable to equity holders of the parent (RMB million)	2,511,111	2,055,511	2.2

A

Items	Current Amount (Jan – Mar)	Description
G r r m	0,55,50/	
G r m b	1,000.00	
G	11,0,1.21	
	-1,5,02. /	
	- , , 01.	
Im m r ()	5,02,01.	
	110, , /	

2.2

The shareholding status of the Top 10 shareholders					
Name of the shareholder	Capacity	Shareholding (%)	Total number of shares held	Number of restricted shares held	Number of shares pledged or frozen
(Gr)	m	1.02	20,1,1	0	
K I I I		1.	5,15,0	0	
10 r		1.22	2, ,52	0	
A		0/	1,21, /	0	
I r m m — J		0/0	1/,000,000	0	
11/ r		0.	1, /,22	0	
b r I m		0.	1,02,0	0	
I r m m —		0.5	12,5,1	0	
A		0.51	11, /,5/	0	
I r m — 01 — 002		0.5	10,12,0	0	

The shareholding status of the Top 10 unrestricted shareholders of tradable shares

Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
K... (Gr...)	20,111	r r r
K... (N...)	5,150	r r r
10...	2,52	r r r
A...	1,217	r r r
J... Gr... b...	1,000,000	r r r
11/...	1,122	r r r
b... I... m...	1,020	r r r
I... mm... —...	12,511	r r r
A... r... m... r...	11,154	r r r
I... m... —... r b... —...	10,120	r r r
— 01 — 002...		A

N : K... I... I... , K... r... m... m... m... ,
r... b... m... .

3 SIGNIFICANT EVENTS

1. A b. A b.

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
...	2,07,000,121.20	1,70,00,205	11%	...
...	2,25,112	12,11,112	11%	...
Income Statement				
Items	Current Amount	Amount of the last period	Ratio of change	Reasons
	(Jan – Mar 2014)	(Jan – Mar 2013)		
...	1,55,000	1,12,500	13%	...
...	1,25,202	20,000,110.1	5%	...
...	1,55,010	2,51,200	-5%	...
...	01,11,112	25,200,010
...	00,000	1,00,000	-5%	...
...	2,11,000	0,000	5%	...
...	00,10,205	25,000,000	-52%	...

() 2/ 201, m (r r r)
r, r rm
I r m m* (上

Consolidated Balance Sheet (Continued)

31 MARCH 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Trade payables	2,015,121.20	1,100,250.00
Other payables		
Provisions		
Income tax payable	1,200,000.00	1,550,000.00
Interest payable	1,150,221.50	1,100,000.00
Other current liabilities	200,210.50	250,221.50
Total current liabilities		
Long-term payables		
Other long-term liabilities	215,000.00	250,000.00
Other long-term liabilities	225,100.00	210,000.00
Long-term payables	110,551.10	1,550,000.00
Other long-term liabilities	11,200.00	2,000.00
Other long-term liabilities	1,211,211.10	1,120,221.50
Total long-term liabilities		
Total liabilities		
Equity		
Share capital		
Reserves		
Retained earnings	500,000.00	500,000.00
Other reserves		
Total equity		
Total assets		

Balance Sheet of the Company

31 March 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and cash equivalents	1,015,000.00	2,111,151.10
Accounts receivable		
Prepaid expenses		
Other receivables		
Inventories		
Intangible assets	121,050.00	255,555.00
Other non-current assets	1,522,000.00	1,522,000.00
Other current assets	1,002,551.10	1,111,211.00
Total current assets	5,112,600.10	5,112,600.10
Total current assets	5,112,600.10	5,112,600.10
Non-current assets:		
A. Long-term investments		
- Investment in subsidiaries		
- Investment in associates		
- Investment in other entities	5,250,000.00	5,100,552.00
Intangible assets		
- Goodwill	1,112,000.00	2,050,000.00
- Other intangible assets		
- Other non-current assets		
- Investment in subsidiaries		
- Investment in associates		
- Investment in other entities	2,011,000.00	2,050,000.00
Total non-current assets	8,373,000.00	7,200,552.00
Total non-current assets	8,373,000.00	7,200,552.00
G. Total assets	13,485,600.10	12,313,152.10
Total assets	13,485,600.10	12,313,152.10

Balance Sheet of the Company (Continued)

31 March 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Trade payables	10,000,000.00	10,000,000.00
Other payables		
Accrued expenses		
Provisions		
Income tax payable	5,500,000.00	5,500,000.00
Dividends payable	1,100,000.00	1,100,000.00
Interest payable	10,220,000.00	10,220,000.00
Other liabilities		
Financial liabilities	1,150,000.00	1,150,000.00
Financial liabilities at fair value through profit or loss	1,000,000.00	1,000,000.00
Other financial liabilities	150,000.00	150,000.00
Non-current liabilities:		
Trade payables	25,000,000.00	25,000,000.00
Other payables	1,050,000.00	1,050,000.00
Accrued expenses		
Provisions		
Income tax payable		
Dividends payable	1,500,000.00	1,500,000.00
Interest payable	2,020,000.00	2,020,000.00
Other liabilities	5,515,500.00	5,515,500.00
Equity attributable to the owners (or equity attributable to shareholders):		
Share capital (ordinary shares)	2,200,000.00	2,200,000.00
Reserves	1,200,000.00	1,200,000.00
Retained earnings	5,401,500.00	5,401,500.00
Other reserves		
Financial assets at fair value through profit or loss	1,050,000.00	1,050,000.00
Financial assets at fair value through other comprehensive income (net of impairment losses)	5,100,000.00	5,100,000.00
Other financial assets	1,120,000.00	1,120,000.00

m
A

Income Statement of the Company

J — M 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I.		
A	2,107,155	207,000.02
	-1,207,155	7,200,000.2
A		
G		
I	27,107,220	27,107,155
I	2,072,220	5,220
II.	-1,020,000	25,500,000.5
	5,000.00	1,020
	2,000,000	5,110.2
I		
III.	-1,207,000	25,707,200.02
I	-1,207,000	25,707,200.02
(1)	-0.00	0.12
(2)	-0.00	0.12
I		5,200.0
II.	-1,207,000	25,007,510.2

A

m J r m J

Consolidated Statements of Cash Flows (Continued)

J – M 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
Interest on long-term debt	5,170.00	
Interest on short-term debt	5,170.00	
Proceeds from the issuance of long-term debt	1,525,150	1,700,000.00
Proceeds from the issuance of short-term debt		
Proceeds from the sale of equity	21,500	
Proceeds from the sale of property, plant and equipment	220,200	1,700,000.00
Proceeds from the sale of investments	125,250	1,700,000
Proceeds from the sale of other assets	20,220	1,250,000
Interest on long-term debt	(1,000,000.00)	(51,750)
Interest on short-term debt	(1,000,000)	(2,000)
Proceeds from the sale of property, plant and equipment	(50,000)	(2,000)
Proceeds from the sale of investments	(1,000,000)	(1,000,000)
IV. Effects of exchange rate fluctuations on cash and cash equivalents	(1,000,000.00)	(1,000,000)
V. Net increase of cash and cash equivalents	(1,000,201)	(55,710)
Beginning balance	2,120,000	2,175,710
VI. Closing balance of cash and cash equivalents	1,119,799	2,120,000

m
A

Statements of Cash Flows of the Company (Continued)

J – M 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
III.1. Issuance of shares:		
III.1.1. Issuance of shares	50,000,000.00	
III.1.2. Issuance of shares		
III.1.3. Issuance of shares	1, /, /, . 1	5, 5, . 1. 0
III.1.4. Issuance of shares	2, 2/, /, . 1	5, 5, . 1. 0
III.1.5. Issuance of shares		
III.1.6. Issuance of shares	10, 1, , 55.55	10, 500,000.00
III.1.7. Issuance of shares	1, /55, 2, /, . . .	/02, . . , 0 . . 2
III.1.8. Issuance of shares	1, 5, . , 2, . 1, .	. 0 , 1 . , 0 . . 2
III.1.9. Issuance of shares	. . , 5/1, 51.	-2 , 211, 0/ . 22
IV. Effects of exchange rate fluctuations on cash and cash equivalents	. , 12 , . . 1	-5, 5, 2, . . . 1
V. Net increase of cash and cash equivalents	-15, 11, 5/2.11	-5, 2, 1, . , 2, .
VI. Closing balance of cash and cash equivalents	51, 2 2, /5. 1	2, 0 0, . 1, 0/ .
VI. Closing balance of cash and cash equivalents	50, 1 5, /0 . 0	1, . /, . 1, 50.

m
A

* F